title: Reversine-treated fibroblasts acquire myogenic competence in vitro and in regenerating skeletal muscle.
abstract: Stem cells hold a great potential for the regeneration of damaged tissues in cardiovascular or musculoskeletal diseases. Unfortunately, problems such as limited availability, control of cell fate, and allograft rejection need to be addressed before therapeutic applications may become feasible. Generation of multipotent progenitors from adult differentiated cells could be a very attractive alternative to the limited in vitro self-renewal of several types of stem cells. In this direction, a recently synthesized unnatural purine, named reversine, has been proposed to induce reversion of adult cells to a multipotent state, which could be then converted into other cell types under appropriate stimuli. Our study suggests that reversine treatment transforms primary murine and human dermal fibroblasts into myogenic-competent cells both in vitro and in vivo. Moreover, this is the first study to demonstrate that plasticity changes arise in primary mouse and human cells following reversine exposure.
authors.affiliation: Department of Medical Chemistry, Biochemistry and Biotechnology, University of Milan, L.I.T.A. via F.lli Cervi 93, 20090 Segrate, Milan, Italy.
authors.forename: Luigi
authors.initials: L
authors.lastname: Anastasia
authors.forename: Maurilio
authors.initials: M
authors.lastname: Sampaolesi
authors.forename: Nadia
authors.initials: N
authors.lastname: Papini
authors.forename: Diego
authors.initials: D
authors.lastname: Oleari
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Lamorte
authors.forename: Cristina
authors.initials: C
authors.lastname: Tringali
authors.forename: Eugenio
authors.initials: E
authors.lastname: Monti
authors.forename: Daniela
authors.initials: D
authors.lastname: Galli
authors.forename: Guido
authors.initials: G
authors.lastname: Tettamanti
authors.forename: Giulio
authors.initials: G
authors.lastname: Cossu
authors.forename: Bruno
authors.initials: B
authors.lastname: Venerando
mesh_terms: D000818:Animals; D002454:Cell Differentiation / Q000187:drug effects; D002459:Cell Fusion; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D018920:Coculture Techniques; D004305:Dose-Response Relationship, Drug; D005347:Fibroblasts / Q000187:drug effects* / Q000502:physiology*; D006801:Humans; D051379:Mice; D009025:Morpholines / Q000494:pharmacology*; D039902:Multipotent Stem Cells / Q000502:physiology*; D018482:Muscle, Skeletal / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D009130:Muscle, Smooth / Q000166:cytology / Q000502:physiology; D010006:Osteoblasts / Q000166:cytology / Q000502:physiology; D011687:Purines / Q000494:pharmacology*; D012038:Regeneration / Q000502:physiology*
chemical_list: D009025:Morpholines; D011687:Purines; C484369:2-(4-morpholinoanilino)-6-cyclohexylaminopurine